RECRUITING

Observational Study of THC Concentrations in Acute Cannabinoid Intoxication

Description

This observational study is being conducted to determine plasma concentrations of tetrahydrocannabinol (THC) and its metabolites, 11-OH-THC and THC-COOH, in plasma of subjects who visit the emergency department due to acute cannabinoid intoxication.

Study Overview

Study Details

Study overview

This observational study is being conducted to determine plasma concentrations of tetrahydrocannabinol (THC) and its metabolites, 11-OH-THC and THC-COOH, in plasma of subjects who visit the emergency department due to acute cannabinoid intoxication.

Multi-center Observational Study of Plasma Concentrations of THC and Its Metabolites in Subjects Visiting Emergency Departments for Acute Cannabinoid Intoxication

Observational Study of THC Concentrations in Acute Cannabinoid Intoxication

Condition
Acute Cannabinoid Intoxication
Intervention / Treatment

-

Contacts and Locations

Aurora

University of Colorado School of Medicine, Aurora, Colorado, United States, 80045

Detroit

Henry Ford Hospital, Detroit, Michigan, United States, 48202

Royal Oak

Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, United States, 48073

Burlington

University of Vermont Medical Center, Burlington, Vermont, United States, 05401

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Subject visits emergency department for acute cannabinoid intoxication as evidenced by the following criteria:
  • 1. Recent cannabis use within the last 12 hours
  • 2. Clinically significant physiological abnormalities associated with cannabis use or problematic behavioral or psychological changes (e.g., altered perception, impaired motor coordination, euphoria, anxiety, a sensation of slowed time, impaired judgment, social withdrawal) that developed during, or shortly after, cannabis use
  • 2. Subject (and/or parent/LAR when required) has the ability to communicate with comprehension with the study personnel at the time of consent/assent and the gathering of data other than plasma samples.
  • 3. Subject (and/or parent/LAR when required) is willing and able to provide informed consent/assent.
  • 1. Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.
  • 2. Individuals under the age of 18 who do not have a parent or legal representative present during the time at the ED.
  • 3. Patients presenting with signs or symptoms attributable to another medical condition or better explained by another mental disorder.
  • 4. Patient presenting with cannabis hyperemesis syndrome (CHS) or cannabis withdrawal syndrome (CWS)
  • 5. Patients who are brought in by law enforcement, i.e., cannabis intoxication associated with a vehicle accident (driving under the influence).

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Anebulo Pharmaceuticals,

Ken Cundy, PhD, STUDY_DIRECTOR, Anebulo Pharmaceuticals Inc.

Study Record Dates

2025-06-30